Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rottnek, M.
Right arrow Articles by Morgello, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rottnek, M.
Right arrow Articles by Morgello, S.
Related Collections
Right arrow HIV
Neurology 2002;58:479-481
© 2002 American Academy of Neurology
Brief Communications

Axonal damage is a late component of vacuolar myelopathy

Matthew Rottnek, MFA, Alessandro Di Rocco, MD, Damien Laudier, BS and Susan Morgello, MD

From the Department of Pathology, Division of Neuropathology, and the Manhattan HIV Brain Bank (Dr. Morgello, M. Rottnek, and D. Laudier), The Mount Sinai School of Medicine, New York; and Department of Neurology (Dr. Di Rocco), Beth Israel Medical Center, Albert Einstein College of Medicine, New York, NY.

Address correspondence and reprint requests to Dr. S. Morgello, Manhattan HIV Brain Bank, Department of Pathology, Box 1134, The Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029; e-mail: susan.morgello{at}mssm.edu

The role of axonopathy in myelin disorders recently has been examined. To investigate axonal pathologic changes in vacuolar myelopathy (VM), semiquantitative immunohistochemical stains for inflammation, axonal damage, and gliosis were performed on spinal cord sections from patients with AIDS with and without VM and from HIV-negative controls. Significant axonal damage was present in only moderate to severe VM, despite inflammation at all stages. The authors conclude that axonal damage is not present in early disease; it is present in moderate to severe vacuolar myelopathy and may contribute to clinical deficits in late stages of this disorder.




This article has been cited by other articles:


Home page
 NeurologyHome page
A. Di Rocco, P. Werner, T. Bottiglieri, J. Godbold, M. Liu, M. Tagliati, A. Scarano, and D. Simpson
Treatment of AIDS-associated myelopathy with L-methionine: A placebo-controlled study
Neurology, October 12, 2004; 63(7): 1270 - 1275.
[Abstract] [Full Text] [PDF]